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Background: Although Taxane is widely used for various types of 
cancer for lung cancer treatment, it is used for no more than ﬁve years. 
Thus, there is not enough data on survival beneﬁt of this new agent. 
In order to investigate the impact of Taxane in the survival of patients 
with NSCLC, a multi-centre retrospective investigation was conducted 
between 1st January 1995 and 31st December 2006. 
Methods: Two groups of patients were included: Group A consisted 
of 403 patients (338 males and 45 females), median 61,00 ± 0.41 
years, treated with Docetaxel (D) in a dose of 100mg/m2 in a two-hour 
infusion, combined with Carboplatin (C) in a dose of AUC = 5.5 in a 
four-week interval up to 8 cycles. Group A consisted of 288 patients 
(266 males and 22 females), median 62 ± 0.47 years, treated with a 
variety of chemotherapeutic agents including Carboplatin in the same 
dose as in group A, following the same number and cycle interval. No 
statistically signiﬁcant differences were observed in age, histological 
type, performance status and TNM staging between the two investi-
gated groups. 
Results: The table shows the median survival in each group of patients. 
Kaplan Mayer method was used to estimate survival curves and log 
rank correlation to check for statistical difference between the two 
groups. 
 N Survival (in days) P
  Median ± SEM (95% CI) (log rank)
Group A 403 356 ±19.3 (318 - 393.9)  
Group B (all cases) 288 250 ± 15.3 (287.4 - 342.5)  
Group A 197 411 ± 40.5 (331.6 - 490) 0.047
Group B (stage IIIb) 173 286 ± 31 (224.6 - 347)  
Group A 206 299 ± 20 (259 - 338.7) 0.007
Group B (stage IV) 115 203 ±26 (151 - 254.7)
A statistical signiﬁcant increase in patients’ survival of group A was 
observed compared to group B, especially in patients of stage IV. More-
over, an increase in survival of group A was observed in stage IIIB, but 
at the limits of signiﬁcancy. 
Conclusion: It seems that D administration increases survival in 
patients with NSCLC especially in stage IV. On the other hand, in stage 
IIIb the survival beneﬁt is at the limits of signiﬁcancy.
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Objective: Recent trials have shown signiﬁcant survival beneﬁt from 
adjuvant chemotherapy after resection of NSCLC. Whether elderly 
patients tolerate platinum-based adjuvant chemotherapy and derive 
the same survival advantage is unknown. This retrospective study 
evaluated the inﬂuence of age on survival, chemotherapy delivery and 
toxicity. 
Methods: Pretreatment characteristics, follow up data and survival 
beneﬁt from treatment were collected. Chemotherapy delivery, toxicity 
1-year survival and disease control rate (DCR) were compared for 99 
treated patients. 
Results: There were 99 elderly patients who were over 75 years. 
Overall DCR was 83%, that for monotherapy, two-drug and three-drug 
were 66.7%, 81% and 91%, respectively. 1-year survival rate was 
38%,15%,25% and 66%, respectively. The toxicity was tolerable. 
Conclusions: chemotherapy improves overall survival in patients aged 
over 75 years with acceptable toxicity. chemotherapy should not be 
withheld from elderly patients.
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Objectives: To investigate the expression of extracellular matrix in 
neo-adjuvant chemotherapy and control group, and its relationship with 
clinical signiﬁcance in non-small cell lung cancer. 
Methods: Expression of extracellular matrix in lung cancer tissues 
was detected in 73 patients by using immunohistochemistry Envision 
method. 
Results: The median survival of 14 patients with low expression of 
ﬁbronetin was 67month, 57 patients with positive expression was 
38month. A signiﬁcant difference existed between the two groups 
(P=0.048). The high expression of laminin in neo-adjuvant chemother-
apy group were negatively related to clinical response.When analyzed 
only patients randomized to neo-ajuvant chemotherapy using cox step-
wise regression analysis, the TNM stage is the only prognosis factor to 
survival. 
Conclusion: Overexpression of some extracellular matrix may be 
involved in the negative chemoresponse rate. The survival time of 
ﬁbronectin and laminin negative patients may be longer than positive 
patients.
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Objective: To investigate efﬁcacy and safety of ﬁrst-line chemo-
therapy of vinorelbine/cisplatin (NP) combined with cyclooxygenase-2 
inhibitor celecoxib in advanced non-small-cell lung cancer (NSCLC) 
patients. 
Methods: 65 NSCLC patients were randomly assigned to Arm A or B. 
In the arm A, 32 patients were treated with vinorelbine 25mg/m2 iv on 
days 1 and 8, cisplatin 75mg/m2 iv on day 1 and celecoxib 400mg bid 
po on days 1 to 12, repeated every 21 days. In the arm B, 33 cases were 
treated with NP regimen alone. 
Results: Compared with arm B, the response rate in arm A was 
35.5% vs 26.7%(P=0.457), disease control rate was 87.1% vs 
66.7%(P=0.058), one-year survival rate was 58.1% vs 36.7%(P=0.094) 
and median survival time was 12 months vs 9.2 months 
(P=0.062)respectively. Subgroup analysis showed that in the 36 adeno-
